AMRN
USDAmarin Corporation plc
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$15.670
Máximo
$15.745
Mínimo
$15.110
Volume
0.06M
Fundamentos da empresa
Capitalização de mercado
326.7M
Setor
Drug Manufacturers - General
País
Ireland
Estatísticas de negociação
Volume médio
0.10M
Bolsa de valores
NCM
Moeda
USD
Faixa de 52 semanas
Relatório de análise de IA
Última atualização: 5/11/2025AMRN Analysis: Navigating Short-Term Volatility in Amarin Corporation Shares
Key Takeaways
- Recent technical indicators show bullish momentum but conflicting signals
- Q3 2025 results triggered sharp price drop, reflecting operational uncertainty
- Stock trades at historical discount to 52-week highs but risks remain
- Fundamental risks outweigh short-term value opportunities
Recent News Impact
Positive Developments
- Scientific Validation (Nov 3, 2025) New analyses presented at AHA Scientific Sessions reinforce Vascepa’s clinical data consistency and mechanism of action.
- FDA Labeling Support (Oct 27, 2025) Company publicly aligned with FDA’s fenofibrate labeling revision, potentially strengthening Vascepa’s competitive differentiation.
Mixed Earnings Release (Oct 29, 2025)
Q3 results highlighted international expansion progress but triggered a 10% single-day crash (from $18.50 to $16.70), suggesting market skepticism about execution risks in the new commercialization model.
Notícias relacionadas
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new
Amarin Reports Third Quarter 2025 Financial Results
Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand,
Amarin Issues Statement Supporting FDA's Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today issued the following statement
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian
Previsão de IABeta
Recomendação de IA
Atualizado em: 10/11/2025, 13:07
58.4% Confiança
Risco e negociação
Ponto de entrada
$15.36
Tomar lucro
$15.93
Parar perda
$14.06
Fatores-chave
Ações relacionadas
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.